Lyon, France – December 5th, 2025 — Advanced BioDesign, a French clinical-stage biotechnology company focused on developing innovative therapies for treatment-resistant cancers, is proud to announce its participation at the American Society of Hematology (ASH) Annual Meeting 2025 with two significant scientific contributions.
Oral Presentation
Room: OCCC – W414CD
Date & Time: Saturday, December 6, 2025 | 2:45 PM – 3:00 PM ET
This presentation will highlight novel insights into the mechanisms of chemoresistance in acute myeloid leukemia (AML) and propose a promising therapeutic approach combining ALDH1A inhibition with hypomethylating agents.
Poster Presentation
Room: OCCC – West Halls B3-B4
Date & Time: Sunday, December 7, 2025 | 6:00 PM – 8:00 PM ET
The poster will present preliminary clinical results from the ODYSSEY trial, evaluating ABD-3001, a first-in-class ALDH inhibitor, in patients with limited treatment options.
The ASH presentation will be available on Advanced BioDesign’s corporate website after the presentation has been held.
***
About Acute Myeloid Leukemia
AML represents a $1.5 billion global market, with limited innovation in frontline and salvage settings. Despite the introduction of targeted therapies, anthracycline-based chemotherapy remains a backbone of treatment, and resistance continues to drive poor outcomes. By addressing a key resistance mechanism, Advanced BioDesign’s ALDH1-targeted approach has the potential to transform the standard of care, expand into combination regimens, and capture significant share in both relapsed/refractory and high-risk AML segments. Beyond AML, ALDH1 inhibition opens opportunities in solid tumors and other hematologic malignancies, creating a multi-billion-dollar market potential.
About ABD-3001
ABD-3001 is the pharmacological form of DIMATE, a first-in-class « suicide » inhibitor of class 1 aldehyde dehydrogenases (ALDH1). This innovative molecule was developed to target a key survival mechanism of cancer cells. It works by blocking ALDH, which tumor cells often use to protect themselves from oxidative stress. By inhibiting this enzyme, DIMATE creates an internal imbalance that leads to cancer cell death, while largely sparing healthy cells. This approach aims to overcome resistance mechanisms to standard chemotherapy.
Currently being evaluated in a Phase 1 clinical trial, ODYSSEY, ABD-3001 could offer an innovative therapeutic option for patients with no remaining treatment alternatives.
About Advanced BioDesign
Advanced BioDesign is a biotechnology company dedicated to developing innovative therapies targeting metabolic vulnerabilities in cancer. The company’s proprietary platform focuses on aldehyde dehydrogenase (ALDH) inhibition to overcome resistance and eradicate cancer stem cells.. Its first drug candidate, ABD-3001, a first-in-class « suicide » inhibitor of class 1 aldehyde dehydrogenases (ALDH1) ius being developed for the treatment of Acute Myeloid Leukemia (AML). In January 2022, Advanced BioDesign obtained authorization from the French Agence Nationale de Sécurité du Médicament (ANSM) to launch its first human clinical trial, ODYSSEY, which began in November 2022. Based in Lyon, Advanced BioDesign is supported and accompanied by Xerys Invest funds, which have been financing its research and development programs since 2013.
For more information: https://www.a-biodesign.com; LinkedIn @Advanced BioDesign
About Xerys Invest
Xerys Invest is a French private equity firm that invests mainly in today’s significant sectors such as Health & Life Sciences and GreenTech. Xerys Invest thus supports companies in industrial sectors that are going through major transformations that meet economic, environmental, and societal challenges and that have strong ambitions in terms of development and international expansion. Xerys Invest stands out on the market both by its modus operandi and long-term strategic and operational support for the companies held in its portfolio and by its offer of traced or pooled investment opportunities offered to investors and the relationship with them. Finally, Xerys Invest has real sector expertise, supported by a strategic committee made up of specialists and recognized experts in key sectors.
For more information: https://www.xerys.com; LinkedIn @Xerys.
Contacts:
Advanced BioDesign
Ismail Ceylan ismail.ceylan@a-biodesign.com
Advanced BioDesign 
Laisser un commentaire